[en] BACKGROUND: Patients with schizophrenia are at high risk of developing metabolic abnormalities. METHOD: A prospective study focusing on metabolic disturbances in patients with schizophrenia, including an oral glucose tolerance test, is currently ongoing at our University Hospital and affiliate services. The prevalence of metabolic abnormalities at baseline was assessed in a cohort of 415 patients with schizophrenia. The sample was divided into 4 groups according to duration of illness: first-episode patients (<1.5 years), recent-onset patients (between 1.5 and 10 years), subchronic patients (between 10 and 20 years) and chronic patients (>20 years). RESULTS: Metabolic abnormalities were already present in first-episode patients, and considerably increased with increasing duration of illness. When compared to the general population matched for age and gender, much higher rates of the metabolic syndrome (MetS) and diabetes were observed for patients with schizophrenia. For MetS, the increase over time was similar to that of the general population. In contrast, the difference in the prevalence of diabetes in patients with schizophrenia and the general population dramatically and linearly increased from 1.6% in the 15-25 age-band to 19.2% in the 55-65 age-band. CONCLUSION: Thus, the current data suggest that on the one hand metabolic abnormalities are an inherent part of schizophrenic illness, as they are already present in first-episode patients. On the other hand, however, our results suggest a direct effect of the illness and/or antipsychotic medication on their occurrence. The data underscore the need for screening for metabolic abnormalities in patients diagnosed with schizophrenia, already starting from the onset of the illness.
Disciplines :
Endocrinology, metabolism & nutrition Psychiatry
Author, co-author :
De Hert, M.
van Winkel, R.
Van Eyck, D.
Hanssens, L.
Wampers, M.
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Peuskens, J.
Language :
English
Title :
Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study.
Publication date :
2006
Journal title :
Clinical Practice and Epidemiology in Mental Health
Raphael TPI: Blood sugar studies in dementia praecox and manic depressive insanity. Arch Neurol Psychiatry 1921, 5:687-709.
Homel P, Casey D, Allison DB: Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr Res 2002, 55:277-284.
Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, Weiden PJ, Cheskin LJ: The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999, 60:215-220.
Jin H, Meyer JM, Jeste DV: Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 2004, 71:195-212.
Allison DB, Casey DE: Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001, 62 Suppl 7:22-31.
Meyer JM, Koro CE: The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004, 70:1-17.
Jin H, Meyer JM, Jeste DV: Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002, 14:59-64.
Scheen AJ, De Hert M: [Drug-induced diabetes mellitus: the exemple of atypical antipsychotics]. Rev Med Liege 2005, 60:455-460.
Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19 Suppl 1:1-93.
De Nayer A, De Hert M, Scheen A, Van Gaal L, Peuskens J: Conference report: Belgian consensus on metabolic problems associated with second-generation antipsychotics. Int J Psy Clin Pract 2005, 9:130-137.
Basu R, Brar JS, Chengappa KN, John V, Parepally H, Gershon S, Schlicht P, Kupfer DJ: The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. Bipolar Disord 2004, 6:314-318.
Brown S: Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997, 171:502-508.
Brown S, Inskip H, Barraclough B: Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000, 177:212-217.
Osby U, Correia N, Brandt L, Ekbom A, Sparen P: Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000, 45:21-28.
Osby U, Correia N, Brandt L, Ekbom A, Sparen P: Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. Bmj 2000, 321:483-484.
Dixon L, Postrado L, Delahanty J, Fischer PJ, Lehman A: The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis 1999, 187:496-502.
Lyketsos CG, Dunn G, Kaminsky MJ, Breakey WR: Medical comorbidity in psychiatric inpatients: relation to clinical outcomes and hospital length of stay. Psychosomatics 2002, 43:24-30.
Weiden PJ, Mackell JA, McDonnell DD: Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004, 66:51-57.
Peuskens H, De Hert M, Van Eyck D, Peuskens J: A case of reversible olanzapine-induced diabetes after switching to risperidone. Adv Schiz Clin Psych 2004, 1:31-33.
Church CO, Stevens DL, Fugate SE: Diabetic ketoacidosis associated with aripiprazole. Diabet Med 2005, 22:1440-1443.
Sanchez-Barranco P: New onset of diabetes mellitus with ziprasidone: a case report. J Clin Psychiatry 2005, 66:268-269.
McCall M, Bourgeois JA: Olanzapine-induced hyperglycemic hyperosmolar nonketotic coma: a case report. J Clin Psychopharmacol 2004, 24:670-673.
Mithat B, Alpaslan T, Bulent C, Cengiz T. Risperidone-associated transient diabetic ketoacidosis and diabetes mellitus type I in a patient treated with valproate and lithium. Pharmacopsychiatry 2005, 38:105-106.
Caro JJ, Ward A, Levinton C, Robinson K: The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002, 63:1135-1139.
Gianfrancesco F, White R, Wang RH, Nasrallah HA: Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003, 23:328-335.
Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA: Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003, 160:290-296.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R: Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002, 26:137-141.
Ryan MC, Collins P, Thakore JH: Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003, 160:284-289.
Expert Panel on Detection and Evaluation of Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
Grundy SM, Cleeman JI, Merz CN, Brewer HBJ, Clark LT, Hunninghake DB, Pasternak RC, Smith SCJ, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
IDF: The IDF Consensus Worldwide Definition of the Metabolic Syndrome. [http://www.idf.org].
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003, 26:S5-S20.
American Diabetes Association, American Psychiatric Association: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596-601.
Rietzschel ER, De Buyzere ML, De Bacquer D, Langlois M, Bekaert S, De Backer G, Gillebert TC: Metabolic syndrome, a map of the cardiovascular damage. Results from the asklepios study in 2528 apparently healthy 35-55 year old subjects. Abstracts Conference European Society of Cardiology. Eur Heart J 2005:110.
Capet F, Debaillie R, Van Oyen H, Tafforeau J: Diabetes. Huidige toestand in België en elementen voor een gezondheidsbeleid. Edited by: Volksgezondheid WI. Available at: http://www.iph.fgov.be/epidemio/ morbidat/nl/zie/ziek04t.pdf,; 1999.
Hanssens L, De Hert M, Wampers M, Reginster JY, Peuskens J: Pharmacological treatment of ambulatory schizophrenic patients in Belgium. Clinical Practice and Epidemiology in Mental Health 2006, in press:.
Wampers M, De Hert M, Van Eyck D, Peuskens J: Somatic medication in hospitalised schizophrenic patients in Belgium. Schizophr Res 2004:67 (Abstracts Winter Workshop on Schizophrenia).
Adam JM, Tarigan NP: Comparison of The World Health Organization (WHO) two-step strategy and OGTT for diabetes mellitus screening. Acta Med Indones 2004, 36:3-7.
Lean ME, Pajonk FG: Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 2003, 26:1597-1605.
Stern MP, Williams K, Haffner SM: Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 2002, 136:575-581.
Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM: The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 2003, 26:3153-3159.
van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J: Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. J Clin Psychiatry 2006 in press.
Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JTJ, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S: Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004, 161:1334-1349.
Scheen A, Van Gaal L, Brohet C, De Backer G, Vissers E, Vandenhoven G: High prevalence of diabetes mellitus and metabolic syndrome in the BEST study ("Belgian Evaluation of Screening and Treatment of high risk patients based on waist and age"). Diabetologia 2005, 48 (Suppl I):A122, 325.
Vivian EM: Type 2 diabetes in children and adolescents - the next epidemic? Curr Med Res Opin 2006, 22:297-306.
Rubenstein AH: Obesity: a modern epidemic. Trans Am Clin Climatol Assoc 2005, 116:103-11; discussion 112-3.
Ford ES, Mokdad AH, Giles WH, Galuska DA, Serdula MK: Geographic variation in the prevalence of obesity, diabetes, and obesity-related behaviors. Obes Res 2005, 13:118-122.
De Hert M, van Winkel R, Van Eyck D, Hanssens I, Wampers M, Scheen A, Peuskens J: Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006, 83:87-93.
McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA: Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80:19-32.
